Tags

Type your tag names separated by a space and hit enter

Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
Biomed Pharmacother. 2008 Feb; 62(2):122-4.BP

Abstract

BACKGROUND

Therapeutic adherence determines the efficacy of treatments in the clinical practice. Especially in chronic asymptomatic diseases large differences exist between therapeutic success in clinical studies and clinical practice. The treatment of osteoporosis using bisphosphonates is considerably influenced by the low adherence of patients due to the complicated drug application.

SUBJECTS AND METHODS

The VIVA study analyzed the preferences of 1635 patients with osteoporosis in Slovakia using a simple questionnaire.

RESULTS

The majority of patients--76% preferred the monthly regime of bisphosphonate therapy, 22% of patients preferred the weekly regimen and only a minority--2% preferred daily application.

CONCLUSION

The results are in agreement with results of the BALTO study in the USA and the SWIFT study in Switzerland showing a clear preference to the monthly regime. The preferences of patients were motivated by various different aspects of improved quality of life, which is offered by the new bisphosphonate regimen once monthly.

Authors+Show Affiliations

5th Department of Internal Medicine, Faculty Hospital, Comenius University, Bratislava, Slovakia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17888616

Citation

Payer, Juraj, et al. "Preferences of Patients Receiving Bisphosphonates--how to Influence the Therapeutic Adherence." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 62, no. 2, 2008, pp. 122-4.
Payer J, Killinger Z, Sulková I, et al. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence. Biomed Pharmacother. 2008;62(2):122-4.
Payer, J., Killinger, Z., Sulková, I., & Celec, P. (2008). Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 62(2), 122-4.
Payer J, et al. Preferences of Patients Receiving Bisphosphonates--how to Influence the Therapeutic Adherence. Biomed Pharmacother. 2008;62(2):122-4. PubMed PMID: 17888616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence. AU - Payer,Juraj, AU - Killinger,Zdenko, AU - Sulková,Ivana, AU - Celec,Peter, Y1 - 2007/08/09/ PY - 2007/07/14/received PY - 2007/07/18/accepted PY - 2007/9/25/pubmed PY - 2008/6/3/medline PY - 2007/9/25/entrez SP - 122 EP - 4 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed Pharmacother VL - 62 IS - 2 N2 - BACKGROUND: Therapeutic adherence determines the efficacy of treatments in the clinical practice. Especially in chronic asymptomatic diseases large differences exist between therapeutic success in clinical studies and clinical practice. The treatment of osteoporosis using bisphosphonates is considerably influenced by the low adherence of patients due to the complicated drug application. SUBJECTS AND METHODS: The VIVA study analyzed the preferences of 1635 patients with osteoporosis in Slovakia using a simple questionnaire. RESULTS: The majority of patients--76% preferred the monthly regime of bisphosphonate therapy, 22% of patients preferred the weekly regimen and only a minority--2% preferred daily application. CONCLUSION: The results are in agreement with results of the BALTO study in the USA and the SWIFT study in Switzerland showing a clear preference to the monthly regime. The preferences of patients were motivated by various different aspects of improved quality of life, which is offered by the new bisphosphonate regimen once monthly. SN - 0753-3322 UR - https://www.unboundmedicine.com/medline/citation/17888616/Preferences_of_patients_receiving_bisphosphonates__how_to_influence_the_therapeutic_adherence_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(07)00135-7 DB - PRIME DP - Unbound Medicine ER -